Adebrelimab
- Generic Name
- Adebrelimab
- Drug Type
- Biotech
- CAS Number
- 2247114-85-6
- Unique Ingredient Identifier
- 1XBY50W1OX
- Background
Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).
- Indication
用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 35
- Registration Number
- NCT06467617
- Locations
- 🇨🇳
Beijing Chest Hospital, Beijing, Beijing, China
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06465563
- Locations
- 🇨🇳
The First Affiliated Hospital，Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
- Target Recruit Count
- 54
- Registration Number
- NCT06464614
- Locations
- 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 216
- Registration Number
- NCT06455410
- Locations
- 🇨🇳
Affiliated cancer hospital and institute of guangzhou medical university, Guangzhou, China
🇨🇳The affiliated panyu central hospital of guangzhou medical university, Guangzhou, China
🇨🇳Liuzhou Workers Hospital, Liuzhou, China
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 30
- Registration Number
- NCT06454578
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT06439589
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Beijing GoBroad Hospital
- Target Recruit Count
- 131
- Registration Number
- NCT06433609
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 35
- Registration Number
- NCT06427239
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Zeng Jian
- Target Recruit Count
- 92
- Registration Number
- NCT06424899
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
- Conditions
- HER2-negative Breast Cancer Brain Metastases
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06418594
- Locations
- 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.